Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. May 15, 2024; 16(5): 2159-2167
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.2159
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.2159
Ref. | Country | Patients | Age | Follow-up | Method to Detect LOH 16q |
Spreafico et al[27], 2013 | Italy | Nonanaplastic unilateral WT of stages I to IV | Median 40 months, range 1 to 172 months | Mean = 73 months, range 35 to 97 months | Microsatellite markers |
Grundy et al[6], 2005 | Australia, New Zealand, Switzerland, and the Netherlands | 1724 patients younger than 16 years at diagnosis with specific WT | < 16 yr | 4 yr | PCR |
Chagtai et al[35], 2016 | 26 countries: 24 in Europe, 1 in Australia, 1 in South America | 586 patients with WT of stages I to IV | Range 6 months to 18 years | M = 68 months | Multiplex Ligation-ependent Probe Amplification |
Messahel et al[7], 2009 | United Kingdom | 426 patients with favorable-histology WT | Not known | 4 yr | Microsatellite markers |
Grundy et al[2], 1994 | United States | 204 patients with histology WT | < 17 yr | M = 1.3 yr (LOH group) or 1.4 yr (control group) | PCR |
Grundy et al[3], 1998 | United Kingdom | 40 patients with sporadic WT | Not known | ≥ 7 yr | PCR |
Klamt et al[4], 1998 | Germany | 73 patients with WT | Mean = 3.48 yr | Not known | PCR |
Skotnicka-Klonowicz et al[36], 2000 | Poland | 58 patients with WT | M = 39 months; range = 2 d to 13 yr | M = 42 months; range = 14–139 months | PCR |
Zhang et al[37], 2002 | China | 30 patients with WT | M = 38 months; range = 2 months to 13 yr | Not known | PCR |
Kullendorff et al[38], 2003 | Sweden | 39 patients with WT | M = 4.2 yr, range 5 months to 15 yr | Range 7 to 160 months | Not known |
Fernandez et al[22], 2017 | United States, Canada, New Zealand and Israel | 110 patients with very low risk WT (defined as stage I favorable histology WT with nephrectomy weight < 550 g and age at diagnosis < 2 yr) | 11.5 months: 0.1 to 23 months | M = 80 months: 5 to 97 months | Multiplex Ligation-ependent Probe Amplification |
Ref. | Selection | Comparability | Outcome | NOS score | Quality |
Spreafico et al[27], 2013 | 4 | 1 | 1 | 6 | Moderate |
Grundy et al[6], 2005 | 4 | 1 | 1 | 5 | Moderate |
Chagtai et al[35], 2016 | 3 | 2 | 2 | 6 | High |
Messahel et al[7], 2009 | 3 | 1 | 2 | 5 | High |
Grundy et al[2], 1994 | 3 | 2 | 2 | 6 | High |
Grundy et al[3], 1998 | 3 | 1 | 2 | 6 | High |
Klamt et al[4], 1998 | 3 | 2 | 2 | 5 | Moderate |
Skotnicka-Klonowicz et al[36], 2000 | 4 | 2 | 1 | 5 | Moderate |
Zhang et al[37], 2002 | 3 | 2 | 2 | 6 | High |
Kullendorff et al[38], 2003 | 3 | 3 | 1 | 5 | Moderate |
Fernandez et al[22], 2017 | 3 | 1 | 2 | 6 | High |
- Citation: Song YH, Li WL, Yang Z, Gao Y, Feng ZP. Loss of heterozygosity for chromosomes 16q in Wilms tumors predicts outcomes: A meta-analysis. World J Gastrointest Oncol 2024; 16(5): 2159-2167
- URL: https://www.wjgnet.com/1948-5204/full/v16/i5/2159.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i5.2159